Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study
In first-line chemoimmunotherapy-treated PD-L1-low/negative NSCLC, baseline LIPI can be used to independently stratify PFS and OS and identify a subgroup with poor prognosis. LIPI may support risk stratification at first-line treatment initiation. Prospective studies are warranted to validate these findings and optimize personalized treatment approaches.
Authors
- Akihiro Yoshimura (ORCID: https://orcid.org/0000-0002-3753-2110)
- Kiyoaki Uryu (ORCID: https://orcid.org/0009-0008-6068-1385)
- Yoshitomo Chihara
- Takeshi Yamada (ORCID: https://orcid.org/0000-0002-6490-758X)
- Hiroshige Yoshioka (ORCID: https://orcid.org/0000-0001-7724-0481)
- Koichi Takayama (ORCID: https://orcid.org/0000-0002-7723-8960)
- Reiko Honda
- Keiko Tanimura (ORCID: https://orcid.org/0000-0002-7826-4466)
- Yuta Yamanaka (ORCID: https://orcid.org/0009-0009-7872-4395)
- SHINSUKE SHIOTSU
- Takayasu Kurata (ORCID: https://orcid.org/0000-0003-4123-3567)
- Takayuki Takeda (ORCID: https://orcid.org/0000-0002-8375-6940)
- Hayato Kawachi (ORCID: https://orcid.org/0000-0002-1673-2260)
- Nobuyo Tamiya (ORCID: https://orcid.org/0000-0003-1410-1104)
Institutions
- Kansai Medical University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Rakuwakai Otowa Hospital (JP)
- Yao Tokushukai General Hospital (JP)
- Kyoto first Red Cross hospital (JP)
- Matsushita Memorial Hospital (JP)
- Asahi General Hospital (JP)
- Japanese Red Cross Society Kyoto Daini Hospital (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105906
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00